fashion -WSS

fashion

author：leisure time 2025-09-06 03:28:32 - browse：95222

LONDON — AstraZeneca said on Monday that a new lung cancer treatment outperformed standard-of-care chemotherapy in a trial, but investors found the results less impressive than anticipated, sending company shares down in early trading.

Based on an interim analysis of a Phase 3 trial, the company said that the drug, datopotamab deruxtecan, led to improvement in progression-free survival in patients non-small cell lung cancer, a primary endpoint of the study. There was also a positive early trend on overall survival, with Susan Galbraith, AstraZeneca’s oncology leader, describing the results as “compelling evidence for the potential role” that the drug could play for patients.

But investors had been hoping for a clearer signal of benefit. Analysts noted that despite the success in progression-free survival, it was not described as a “clinically meaningful” improvement, which, as J.P. Morgan analysts wrote, “we believe the market would have liked to have seen.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Will an HIV vaccine ever be a reality?

focus

WSS

IVG is promising — but it won’t replace IVF quite yet

IVG is promising — but it won’t replace IVF quite yet

STAT Summit: Ending the crisis of Black deaths in the U.S.

Some top drug companies are starting to take action on climate

Results on Novartis prostate cancer therapy could expand its use

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

focus

fashion

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Malaria cases in Florida and Texas: Here’s what you need to know

STAT Readout Newsletter: Biotech news today

Supreme Court strikes down use of affirmative action

J&J lung cancer data amount to new salvo against AstraZeneca

Supreme Court strikes down use of affirmative action

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

State Dept. review finds Biden bears some blame for Afghanistan failures

Setback for rare diseases as Taysha Gene Therapies pulls back

explore

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

FDA sees ‘potential systemic bias’ in Amgen’s KRAS drug trial

WHO recommends second malaria vaccine

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

Flu, Covid vaccination rates decline, new survey data show

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

focus

focus

knowledge

Wikipedia